Triple Metformin, SGLT-2, DPP-4 Therapy Outperforms Dual Therapy in T2DM: Study
Pakistan: Triple therapy combining metformin, SGLT-2 inhibitors, and DPP-4 inhibitors achieves superior glycemic control compared with dual therapy, improving blood glucose control without significant additional safety concerns. However, reduced tolerability may impact patient adherence over the long term, highlighting the need to balance efficacy with treatment acceptability when selecting therapy. These findings were reported in a systematic review and meta-analysis published in the journal Medicine by Abdul Fatah Malik and colleagues.
Type 2 diabetes mellitus (T2DM) often requires treatment intensification when blood glucose levels remain uncontrolled despite standard therapy. To assess the benefits of a more intensive approach, researchers evaluated the efficacy and safety of triple oral therapy combining metformin, an SGLT-2 inhibitor, and a DPP-4 inhibitor versus dual therapy with metformin plus either agent.
The researchers conducted a systematic review and meta-analysis of randomized controlled trials identified through PubMed, Embase, Scopus, and Web of Science up to January 2026. Eight studies involving 2,606 adults with T2DM were included. Outcomes assessed included HbA1c, fasting plasma glucose, body weight, achievement of HbA1c below 7%, and adverse events.
The following were the key findings:
- Triple therapy significantly reduced HbA1c levels compared with dual therapy (SMD: −0.54).
- Patients receiving triple therapy were about twice as likely to achieve the target HbA1c level of less than 7% compared with those on dual therapy (RR: 2.02).
- Triple therapy resulted in greater reductions in fasting plasma glucose than dual therapy (SMD: −0.30).
- The three-drug regimen produced modest but significant reductions in body weight (SMD: −0.14).
- No significant difference was observed in the overall incidence of adverse events between triple and dual therapy (RR: 0.97).
- Rates of hypoglycemia were comparable between the two treatment approaches (RR: 1.32).
- Patients receiving triple therapy were more likely to discontinue treatment because of adverse events compared with those receiving dual therapy (RR: 2.62).
The authors acknowledged that most included studies had relatively short follow-up periods of four to six months, limiting assessment of long-term glycemic durability and effects on cardiovascular, renal, and diabetes-related outcomes. Differences in comparator regimens, relatively uniform study populations, and limited data on treatment satisfaction, quality of life, and adherence may also affect the broader applicability of the findings.
The researchers concluded that triple oral therapy with metformin, an SGLT-2 inhibitor, and a DPP-4 inhibitor is an effective option for treatment intensification in T2DM. The regimen provides superior glycemic control and modest weight reduction without major safety concerns, although tolerability and long-term adherence should be considered in clinical decision-making.
Reference:
Malik, Abdul Fatah MBBSa; Kashish, Fnu MBBSb; Shivani, Fnu MBBSc; Kumar, Somesh MBBSd; Kumari, Vanesha MBBSe; Haseeb, Abdul MBBSb; Mujtaba, Ahmad MBBSf; Raheem, Abdur MBBSg; Ali, Syed Muhammad Sinaan MBBSf; Saleh, Usama MBBSh; Ahmad, Tagwa Kalool Fadlalla MBBSi,*. Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Medicine 105(22):p e49050, May 29, 2026. | DOI: 10.1097/MD.0000000000049050
Next Story